Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema

* Male or female age 18 years or older * Macular edema due to diabetic retinopathy * Best-corrected visual acuity in the study eye of 20/40 to 20/400 * Central subfield thickness ≥ 250 microns by OCT * Females of childbearing potential must have a negative serum pregnancy test at Screening * Male subjects must or be: 1) surgically sterilized for at least 6 months, or 2) use an appropriate method of barrier contraception (e.g., condoms with spermicide) and advise any sexual partner of child-bearing potential that she must also use a reliable method of contraception (e.g., hormonal contraceptive, intrauterine device, diaphragm with spermicide) during the study and for 30 days from study drug administration. * Ability to understand the nature of the study and give written informed consent * Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures

* Any indication of irreversible vision loss such as significant atrophy, scarring, fibrosis, or hyperpigmentation in the fovea * Presence of significant ocular abnormalities in the study eye that prevent retinal assessment, including media opacities, cataract, or inadequate papillary dilation * Presence of vision loss from another ocular disease other than DME * History of any intraocular surgery within 3 months of Baseline * History of intraocular injection of anti-VEGF agent or steroids within 3 months of Baseline * History of laser photocoagulation for macular edema within 4 months prior to Baseline * Uncontrolled hypertension \> 140 systolic or \> 95 diastolic * HbA1C ≥ 12% * Creatinine: \> 1.5 x upper limit of normal (ULN) * Alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyl transferase (GGT): \> ULN * White blood cells (WBC), hematocrit, and platelets: \< lower limit of normal (LLN) * Heart rate \< 60 beats per minute (bpm) or history of clinically significant bradycardia * History of human immunodeficiency virus (HIV), chronic hepatitis B, or chronic hepatitis C infections * Subjects with infections requiring hospitalization and/or antibiotic treatment 14 days prior to Baseline * Subjects with any medical condition that in the judgment of the investigator could poise unacceptable risk to the subject or compromise interpretation of the data to be collected